Skip to content
TrialScanner

NCT03757325

Study to Evaluate DNL747 in Subjects With Alzheimer's Disease

Phase 1CompletedDNLILead

Registry record

Lead sponsor
Denali Therapeutics Inc.
Conditions
Alzheimer Disease
Primary completion
Dec 5, 2019Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT03757325 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.